SR-17018 EU

SR-17018 is a novel small-molecule agonist targeting the μ-opioid receptor (MOR), exhibiting a pronounced bias towards G protein signaling over β-arrestin 2 recruitment. This pharmacological profile aims to retain potent analgesic effects while mitigating common opioid-induced adverse effects such as respiratory depression, tolerance, and dependence.

Pharmacodynamics and Mechanism of Action

SR-17018’s unique action stems from its selective activation of G protein pathways associated with MOR, minimizing β-arrestin 2-mediated signaling. This bias is believed to underlie its reduced propensity for inducing respiratory depression and other side effects commonly associated with traditional opioids.

Farmacokinetiek

• Absorptie: SR-17018 demonstrates good oral bioavailability.
• Distributie: It effectively crosses the blood-brain barrier, ensuring central nervous system activity.
• Stofwisseling: The compound undergoes hepatic metabolism, primarily via cytochrome P450 enzymes.
• Elimination: SR-17018 has a half-life of approximately 6 hours, supporting twice-daily dosing regimens.

Efficacy in Preclinical Models

In various animal models, SR-17018 has shown:

• Potent antinociceptive effects comparable to morphine.
• Sustained efficacy upon repeated administration, indicating a lower tendency for tolerance development.
• Effectiveness in neuropathic pain models, such as paclitaxel-induced allodynia.

Safety Profile

Compared to traditional opioids, SR-17018 exhibits:

• Reduced respiratory depression.
• Lower incidence of constipation.
• Minimal development of physical dependence.

Dosering en toediening

In preclinical studies, SR-17018 has been administered orally at doses ranging from 1 to 48 mg/kg, with 24 mg/kg/day being effective for sustained analgesia. However, optimal dosing in humans remains to be established through clinical trials.

Mogelijke bijwerkingen

While SR-17018 shows a favorable safety profile, potential side effects observed in animal studies include:

• Mild sedation.
• Gastrointestinal disturbances at higher doses.

Harm Reduction Considerations

SR-17018’s pharmacological characteristics suggest a lower abuse potential. Nonetheless, harm reduction strategies, including patient education and monitoring, remain essential to mitigate risks associated with opioid therapy.

Conclusie

SR-17018 represents a promising advancement in opioid pharmacotherapy, offering potent analgesia with a reduced side effect burden. Ongoing research is necessary to fully elucidate its clinical potential and safety in human populations.

Note: SR-17018 is currently under preclinical investigation. Clinical efficacy and safety in humans have yet to be established.

Why Buy SR-17018 from RECHEMCO?

★ We hebben een lange handelsgeschiedenis in de markt, dus je profiteert van onze ervaring.
★ SR-17018 werd getest en geverifieerd.
★ We accept various payment methods such as Bitcoin, all the main cryptocurrencies, Credit Card and bank wire.

Wat u ontvangt bij aankoop SR-17018 van RECHEMCO?

- Een verzegelde zak van aluminiumfolie met de hoogste kwaliteit SR-17018
• crystalline powder
- 99% Zuiverheid